Biogen’s second quarter witnessed a positive market response, buoyed by notable revenue growth and a significant beat on non-GAAP profit relative to analysts’ expectations. Management cited strong commercial execution across its growth product portfolio as a primary driver, especially the rapid adoption of high-dose SPINRAZA and momentum from newly acquired Apellis products, SYFOVRE and Empaveli. CEO Christopher Viehbacher emphasized that, for the first time, Biogen’s growth portfolio now exceeds its legacy multiple sclerosis (MS) segment, underscoring a successful shift towards newer therapies. The integration of Apellis products was highlighted as a key factor contributing to near-term revenue stability and improved execution across launches.
Is now the time to buy BIIB? Find out in our full research report (it’s free for active Edge members).
Biogen (BIIB) Q2 CY2026 Highlights:
- Revenue: $2.74 billion vs analyst estimates of $2.44 billion (3.4% year-on-year growth, 12.1% beat)
- Adjusted EPS: $3.60 vs analyst estimates of $2.05 (75.8% beat)
- Management raised its full-year Adjusted EPS guidance to $16.35 at the midpoint, a 10.8% increase
- Operating Margin: 5.5%, down from 30% in the same quarter last year
- Market Capitalization: $30.8 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Biogen’s Q2 Earnings Call
- Chris Schott (JPMorgan): Asked for metrics on high-dose SPINRAZA adoption and switchbacks. President Alisha Alaimo detailed strong initial uptake, including new patient starts and a reversal of previous trends toward oral therapies.
- Umer Raffat (Evercore): Inquired about expectations for lupus trial outcomes and differentiation. Head of Development Dr. Priya Singhal described efforts to design robust trials and manage placebo response, but refrained from specific predictions, emphasizing unmet need.
- Marc Goodman (Leerink Partners): Requested insight on SYFOVRE’s patient and physician growth. Alaimo highlighted quality of growth, improved sentiment, and a strategic shift toward targeted direct-to-consumer campaigns and workflow improvements for physicians.
- Salveen Richter (Goldman Sachs): Questioned the competitive positioning and safety of the BTK inhibitor BIIB091. Dr. Singhal noted compelling efficacy data but cited a crowded market and ongoing evaluation of next steps.
- Evan Seigerman (BMO Capital Markets): Asked what data would validate felzartamab in AMR as a $2 billion opportunity. CEO Viehbacher stressed the high unmet need and substantial market size, noting the importance of upcoming Phase 3 results.
Catalysts in Upcoming Quarters
Over the next several quarters, the StockStory team will be monitoring (1) the pace and breadth of adoption for new launches such as high-dose SPINRAZA and LEQEMBI IQLIK, (2) readouts from five pivotal late-stage clinical trials across autoimmune, renal, and neurology indications, and (3) realization of synergy targets and cost control following the Apellis integration. The company’s ability to execute on product launches and successfully diversify its portfolio will be key areas of focus.
Biogen currently trades at $208, up from $205.61 just before the earnings. Is there an opportunity in the stock? See for yourself in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.